(redirected from plasmacytomas)
Also found in: Thesaurus, Medical.
Related to plasmacytomas: soft tissue plasmacytoma
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.plasmacytoma - neoplasm of plasma cells (usually in bone marrow)
neoplasm, tumor, tumour - an abnormal new mass of tissue that serves no purpose
Mentioned in ?
References in periodicals archive ?
9, 72, 73) As summarized in Table 2, the combination of BCL1, CD19, CD45, CD56, and CD117 is sufficient to distinguish PCs derived from PCMs and/or plasmacytomas from B-cell lymphomas, even in cases in which there is exuberant plasmacytic differentiation.
These patients were predominantly in an early International Staging System stage, showed non-secretory and light-chain variants, and significant association with extramedullary plasmacytomas.
This is in concurrence with the finding by Bangerter et al, [12] who observed in their study that majority of the plasmacytomas with extramedullary presentation showed anaplastic morphology.
However, 3% of cases may develop extramedullary involvement, defined as the formation of solid plasmacytomas outside the bone marrow.
This proliferation results in extensive skeletal involvement, with osteolytic lesions, anaemia, hypercalcaemia and/or soft tissue plasmacytomas (2).
Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas.
The plasma cells may collect in the bone to make small tumours known as plasmacytomas.
Although typically found within the bone marrow, extraosseous myelomatous collections referred to as extramedullary plasmacytomas (EMPs) are rarely found in the head and neck region, gastrointestinal tract, and central nervous system.
Plasmacytomas are manifestations of plasma cell tumors that may arise in any part of the body from the plasma cells in the bone marrow or from the mucosal surfaces when extramedullary.
Plasmacytomas are rare tumours arising from plasma cells and are divided into solitary bone plasmacytomas (SBPs) and extramedullary plasmacytomas (EMPs), with the latter accounting for less than 3% of all plasma cell tumours.